Constellation Pharmaceuticals, Inc. (CNST)

$33.99

0.00 (0.00%)
Rating:
Recommendation:
-
Symbol CNST
Price $33.99
Beta 2.580
Volume Avg. 1.57M
Market Cap 1.630B
Shares () -
52 Week Range 17.0-39.3
1y Target Est -
DCF Unlevered CNST DCF ->
DCF Levered CNST LDCF ->
ROE -33.12% Strong Sell
ROA -35.01% Strong Sell
Operating Margin -
Debt / Equity 6.72% Neutral
P/E -
P/B 4.31 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CNST news


Mr. Jigar Raythatha
Healthcare
Biotechnology
Nasdaq Global Select

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. The company is also developing CPI-0209 that is in Phase I dose escalation portion of a Phase I/II clinical trial to treat solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.